Aventis Pharma to Create New Gencell Entity Aventis Pharma and Introgen to Restructure Their Collaboration in Gene Therapy
(PR Newswire)...INGN 201 uses a proprietary adenoviral technology to target the p53 gene to kill cancer cells and suppress tumor growth through multiple molecular mechanisms.......Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain and breast cancer.......INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....- Apr 02 5:06 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010402/dam050b_3.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines